EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
Key Highlights
- ➤EyePoint schedules four November investor-conference fireside chats
- ➤EYP-1901 LUCIA Phase 3 wet AMD results presentation set for December 3
- ➤COMO/CAPRI Phase 3 DME trial update presentation set for December 3
- ➤EyePoint will present EYP-1901 data at FLORetina-ICOOR December 4-5
Expert Statements
Anat Loewenstein, M.D., Presenter
“LUCIA Pivotal Phase 3 Trial Results: Primary Efficacy and Safety of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD”
Ramiro Ribeiro, M.D., Ph.D., Presenter and panelist
“Significance of IL-6 Inhibition in DME and Update on Phase 3 COMO/CAPRI Trials”
Ramiro Ribeiro, M.D., Ph.D., Panelist
“From Controlling Neovascularization to Restoring Vascular Function”
Tarek S. Hassan, M.D., Presenter
“EYP-1901 in the Management of Macular Disease”
David S. Boyer, M.D., Presenter
“Bioerodible EYP-1901 (vorolanib intravitreal insert) for Diabetic Macular Edema: Overview of COMO and CAPRI Pivotal Phase 3 Trials”
Charles C. Wykoff, M.D., Presenter
“LUCIA Pivotal Phase 3 Trial Efficacy and Safety Results of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD”
WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences: * Guggenheim 3(rd) Annual Healthcare Innovation Conference Forum: Fireside Chat Date: November 9, 2026 Time: 2:30 pm EST
* Stifel 2026 Healthcare Conference Forum: Fireside Chat Date: November 10, 2026 Time: 1:20 pm EST
Get started
Create a free account to read the full story.